Proprium Biotech Secures Tens of Millions in Series A Funding to Advance Liver Disease Diagnostics

VCBeat has learned that Hangzhou Puwang Biotechnology Co., Ltd., a quasi-unicorn enterprise in the field of liver disease diagnosis, recently announced the completion of its Series A financing round, raising tens of millions of yuan. The round was led by Gaoke Xinjun. The funds will be primarily used for the market promotion of the company’s core product, Chitinase-3-like protein 1 (CHI3L1), as well as for expanding domestic and international distribution channels. This investment will significantly advance Puwang Biotechnology’s vision of “a world without severe liver disease.”

Since its establishment in 2010, Puwang Biotechnology has focused on the field of liver disease diagnosis and dedicated itself to research and development. The company has successively developed multiple exclusive products in China, including Chitinase-3-like protein 1 (CHI3L1) and a triple-marker test for liver cancer. CHI3L1 provides a more sensitive biomarker for staging and dynamic monitoring of liver fibrosis, enabling timely and effective screening and differentiation of potential liver fibrosis in asymptomatic patients (e.g., those with normal transaminase levels). This addresses certain challenges and pain points in liver disease diagnosis and fills the market gap for accurate, quantitative detection of liver fibrosis. The CHI3L1 diagnostic kits developed by the company have obtained registration certificates on multiple technology platforms, including chemiluminescence and ELISA, and have been approved for pricing in multiple provinces and cities. After years of academic promotion, the clinical significance of CHI3L1 has been increasingly recognized by clinical experts both domestically and internationally. CHI3L1 has been included in the 2019 edition of the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China."

In May 2020, Puwang Biology received lead investment from Gaoke Xinjun, making its prospects even more promising!

Hangzhou Proprium Biotech Co., Ltd. (Proprium Biotech Company Limited), established in 2010 and located in the Xiasha Economic and Technological Development Zone of Hangzhou, possesses personalized medical diagnostic technologies in the fields of liver cancer, liver fibrosis, and multiple other cancers. Holding fully independent intellectual property rights, the company has successfully developed a variety of novel diagnostic products based on these technologies.

The company is dedicated to building an innovative platform that integrates diagnostic reagents with supporting instrumentation, enabling clinical applications for the precise diagnosis and personalized treatment of liver diseases. Dr. Lin Biaoyang, founder of Puwang Biology, is a renowned expert in the field of international systems biology and a pioneer of “precision medicine.” As early as 2004, he published an article in Science advocating for “3P Medicine.”

Neovision Capital is a professional firm specializing in venture capital, innovation-driven investments, and mergers and acquisitions within the healthcare and high-tech sectors. Since its establishment in late 2015, it has invested in multiple high-growth enterprises in the biopharmaceutical and high-tech fields. Portfolio companies of Neovision Fund I include representative projects such as BioGerm (688399), Rendu Biotechnology, Jiangsu Genostem Medical Technology, Zhengya Dental, Allist Pharmaceutical, Huahao Zhongtian, ACROBiosystems, Yimai Yangguang, and Bocsoft. Since the inception of Fund II earlier this year, it has completed two investments in the broader healthcare sector: Puwang Biology and Hualan Shares.